Endogenous Bufadienolides, Fibrosis and Preeclampsia

Vitaliy A Reznik; Vladimir A Kashkin; Natalia I Agalakova; C David Adair; Alexei Y Bagrov

doi:10.1155/2019/5019287

Endogenous Bufadienolides, Fibrosis and Preeclampsia

Cardiol Res Pract. 2019 Dec 12:2019:5019287. doi: 10.1155/2019/5019287. eCollection 2019.

Authors

Vitaliy A Reznik¹, Vladimir A Kashkin^{2

3}, Natalia I Agalakova³, C David Adair⁴, Alexei Y Bagrov³

Affiliations

¹ Department of Obstetrics and Gynecology, School of Pediatric Medicine, St. Petersburg 194353, Russia.
² Valdman Institute of Pharmacology, Pavlov Medical University, St. Petersburg 197022, Russia.
³ Sechenov Institute of Evolutionary Physiology and Biochemistry, 44 Torez Prospect, St. Petersburg 194223, Russia.
⁴ Department of Obstetrics and Gynecology, University of Tennessee, Chattanooga, TN, USA.

Abstract

Frequency of preeclampsia has no tendency to decrease, and it still takes the leading position in the structure of maternal mortality and morbidity worldwide. In this review, we present the "fibrotic concept" of the etiology and pathogenesis of preeclampsia which involves system consisting of Na/K-ATPase and its endogenous ligands including marinobufagenin. New therapy of preeclampsia includes modulation of the Na/K-ATPase system by immunoneutralization of the marinobufagenin and use of mineralocorticoid antagonists which are capable to impair marinobufagenin-Na/K-ATPase interactions.

Publication types

Review